BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11378266)

  • 1. Leukemia blast-induced T-cell anergy demonstrated by leukemia-derived dendritic cells in acute myelogenous leukemia.
    Narita M; Takahashi M; Liu A; Nikkuni K; Furukawa T; Toba K; Koyama S; Takai K; Sanada M; Aizawa Y
    Exp Hematol; 2001 Jun; 29(6):709-19. PubMed ID: 11378266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum-free generation and quantification of functionally active Leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes.
    Kufner S; Fleischer RP; Kroell T; Schmid C; Zitzelsberger H; Salih H; de Valle F; Treder W; Schmetzer HM
    Cancer Immunol Immunother; 2005 Oct; 54(10):953-70. PubMed ID: 15789235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22.
    Olsnes AM; Ryningen A; Ersvaer E; Bruserud Ø
    J Interferon Cytokine Res; 2008 May; 28(5):297-310. PubMed ID: 18547160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficient generation of immunocompetent dendritic cells from leukemic blasts in acute myeloid leukemia: a local experience.
    Bagheri K; Alimoghadam K; Pourfathollah AA; Hassan ZM; Hajati J; Moazzeni SM
    Pathol Oncol Res; 2009 Jun; 15(2):257-67. PubMed ID: 18807213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The induction and function study on dendritic cells derived from blasts from patients with acute myelogenous leukemia.
    Meng DM; Zhao CT; Wu SL; Wang BZ; Lü ZH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Oct; 12(5):625-31. PubMed ID: 15498123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of CD86 in acute myelogenous leukemia is a marker of dendritic/monocytic lineage.
    Re F; Arpinati M; Testoni N; Ricci P; Terragna C; Preda P; Ruggeri D; Senese B; Chirumbolo G; Martelli V; Urbini B; Baccarani M; Tura S; Rondelli D
    Exp Hematol; 2002 Feb; 30(2):126-34. PubMed ID: 11823047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of the concentration of autologous serum for generation of leukemic dendritic cells from acute myeloid leukemic cells for clinical immunotherapy.
    Choi BH; Kang HK; Park JS; Kim SK; Pham TN; Zhu XW; Cho D; Nam JH; Chung IJ; Kim YJ; Rhee JH; Kim HJ; Lee JJ
    J Clin Apher; 2006 Dec; 21(4):233-40. PubMed ID: 17120232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses.
    Choudhury BA; Liang JC; Thomas EK; Flores-Romo L; Xie QS; Agusala K; Sutaria S; Sinha I; Champlin RE; Claxton DF
    Blood; 1999 Feb; 93(3):780-6. PubMed ID: 9920826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Interferon (IFN)α in "Cocktails" for the Generation of (Leukemia-derived) Dendritic Cells (DCleu) From Blasts in Blood From Patients (pts) With Acute Myeloid Leukemia (AML) and the Induction of Antileukemic Reactions.
    Hirn Lopez A; Deen D; Fischer Z; Rabe A; Ansprenger C; Stein K; Vogt V; Schick J; Kroell T; Kraemer D; Kolb HJ; Tischer J; Schmid C; Schmetzer H
    J Immunother; 2019 Jun; 42(5):143-161. PubMed ID: 31090655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [In vitro stimulation of specific antileukemia T-cell response by dendritic cells derived from CD14+ acute monocytic leukemia cells].
    Sheng LX; Xie XB; Qiu GQ; Gu WY; Wang ZL; Wu HQ
    Ai Zheng; 2005 Nov; 24(11):1338-44. PubMed ID: 16552959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells.
    Draube A; Beyer M; Wolf J
    Eur J Haematol; 2008 Oct; 81(4):281-8. PubMed ID: 18573171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells.
    Köhler T; Plettig R; Wetzstein W; Schmitz M; Ritter M; Mohr B; Schaekel U; Ehninger G; Bornhäuser M
    Stem Cells; 2000; 18(2):139-47. PubMed ID: 10742386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Investigation on specific killing acute leukemia cell reaction of the cytotoxic T lymphocyte induced by dendritic cell pulsed with frozen-thawed antigen].
    He B; Qiu G; Xie X
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2004 Dec; 21(6):974-8. PubMed ID: 15646345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD80-Transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens.
    Mutis T; Schrama E; Melief CJ; Goulmy E
    Blood; 1998 Sep; 92(5):1677-84. PubMed ID: 9716596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential.
    Liepert A; Grabrucker C; Kremser A; Dreyssig J; Ansprenger C; Freudenreich M; Kroell T; Reibke R; Tischer J; Schweiger C; Schmid C; Kolb HJ; Schmetzer H
    Cell Immunol; 2010; 265(1):23-30. PubMed ID: 20663492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions.
    Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schweiger C; Nuessler V; Schmid C; Kolb HJ; Schmetzer HM
    Scand J Immunol; 2005 Jul; 62(1):86-98. PubMed ID: 16091128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells.
    van Luijn MM; van den Ancker W; Chamuleau ME; Zevenbergen A; Westers TM; Ossenkoppele GJ; van Ham SM; van de Loosdrecht AA
    Cancer Res; 2011 Apr; 71(7):2507-17. PubMed ID: 21310823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical grade expansion of CD45RA, CD45RO, and CD62L-positive T-cell lines from HLA-compatible donors: high cytotoxic potential against AML and ALL cells.
    Barbui AM; Borleri G; Conti E; Ciocca A; Salvi A; Micò C; Introna M; Rambaldi A
    Exp Hematol; 2006 Apr; 34(4):475-85. PubMed ID: 16569594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of interleukin-4 and interleukin-6 on the proliferation of CD34+ and CD34- blasts from acute myelogenous leukemia.
    Akashi K; Harada M; Shibuya T; Eto T; Takamatsu Y; Teshima T; Niho Y
    Blood; 1991 Jul; 78(1):197-204. PubMed ID: 1712640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of T cell anergy by the treatment with IL-10-treated dendritic cells.
    Zheng Z; Narita M; Takahashi M; Liu A; Furukawa T; Toba K; Aizawa Y
    Comp Immunol Microbiol Infect Dis; 2004 Mar; 27(2):93-103. PubMed ID: 14690719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.